2022 Savings Offer for AJOVY is here. Learn more
Efficacy for AJOVY

Sustained efficacy1 with no evidence of “wearing off”2

Patients experienced significantly more migraine-free days with AJOVY vs placebo in the HALO + Long-Term Extension Studies1,3-5

See Study Design

Chronic Migraine

Consider limitations of Long-Term Extension study design when interpreting efficacy results.

Patients randomized to monthly dosing had a mean baseline of 12.8 headache days of at least moderate severity per month and experienced, on average1:
5.1 fewer headache days at month 3 vs 3.3 with placebo (P<0.001).1,3

Patients randomized to quarterly dosing had a mean baseline of 13.2 headache days of at least moderate severity per month and experienced, on average1:
4.7 fewer headache days at month 3 vs 3.3 with placebo (P<0.001).1,3

*Mean baseline of 12.8 headache days of at least moderate severity per month with monthly dosing.1
Reduction in monthly average number of headache days from the Long-Term Extension study was 6.4 with quarterly dosing.3

No evidence of “wearing off” with AJOVY was
observed from one dose to the next2

POST HOC WEEKS 1-3 VS 4

Mean number of weekly migraine days during weeks 1-3 vs week 4 at months 3, 6, 9, and 15 with monthly dosing2‡

Generated with Avocode.Group 2717Rectangle 870 copy 2Path 2254Group 2463Rectangle 870 copyPath 2252Path 2253Rectangle 537Rectangle 537Group 2718Rectangle 534Rectangle 534 copy 2Path 2238Path 2240Path 2242Path 2246Path 2243Path 2249Rectangle 534Rectangle 534 copy 2Path 2244Path 2245Rectangle 534Rectangle 534 copy 2Path 2247Path 2248Rectangle 534Rectangle 534 copy 2Path 2250Path 2251Rectangle 517 copyRectangle 517 copy 2Rectangle 517 copy 3Rectangle 517 copy 4Rectangle 517 copy 6Rectangle 517 copy 5Path 2233Path 2234Path 2235Path 2236Path 2239Path 2237Path 2241linesPath 2550

POST HOC WEEKS 1-2 VS 11-12

Mean number of weekly migraine days in weeks 1-2 vs weeks 11-12 with quarterly dosing2‡

Generated with Avocode.Group 2458Rectangle 870 copy 2Path 2293Group 2451Rectangle 870 copyPath 2291Path 2292Rectangle 537Rectangle 537Group 2713Rectangle 534Rectangle 534 copyPath 2279Path 2287Rectangle 534Rectangle 534 copyPath 2289Path 2294linesPath 2288Path 2290Rectangle 517 copyRectangle 517 copy 2Rectangle 517 copy 3Rectangle 517 copy 4Rectangle 517 copy 6Rectangle 517 copy 5Path 2280Path 2281Path 2282Path 2283Path 2284Path 2285Path 2286Path 2548

For all post hoc analyses, no determination of statistical significance can be made and no conclusions should be drawn.

Study design: Of the patients who rolled over from the HALO studies, 611 from the HALO CM study (monthly, n=305; quarterly, n=306) and 432 from the HALO EM study (monthly, n=215; quarterly, n=217) had received AJOVY injection during the respective HALO study and were included in post hoc analyses during the long-term, open-label extension study.2

In clinical trials, AJOVY reduced migraine days by 50% or more for some patients1

CHRONIC MIGRAINE

Secondary endpoint

Reduction

in monthly average headache days with monthly dosing

40.8% vs 18.1%

with placebo
(P<0.001)1

Exploratory analyses

Reduction

in monthly average headache days with monthly dosing

20.6% vs 10.4%

with placebo
(Exploratory analysis)3

Exploratory analyses

Reduction

in monthly average headache days with monthly dosing

7.5% vs 4.2%

with placebo
(Exploratory analysis)3

For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.

Similar reductions seen with quarterly dosing in chronic migraine patients§

§With quarterly dosing for chronic migraine patients, reduction in monthly average headache days of at least moderate severity: 37.6% of patients achieved a ≥50% reduction vs 18.1% with placebo (P<0.001), 20% achieved a ≥75% reduction vs 10.4% with placebo (exploratory analysis), and 7.7% achieved 100% reduction vs 4.2% for placebo (exploratory analysis).1,3

What to explore next